Результаты поиска

Rice bran arabinoxylan compound and quality of life of cancer patients (RBAC-QoL): Study protocol for a randomized pilot feasibility trial.

IntroductionRice bran arabinoxylan compound (RBAC) is a nutraceutical for enhancing a depleted immune system during and after cancer treatment. This pilot feasibility trial aims to evaluate the effects of RBAC on cancer patients' quality of life during active treatment, compared to placebo, using a validated questionnaire. Other outcome measures include changes in inflammatory and nutritional status, cytokine profile, and gut microbiota.Methods/designThe study will recruit 50 participants from a regional cancer center in Australia. Patients aged 18-70, diagnosed with solid organ cancers stage

A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.

BACKGROUND Approximately 10% to 15% of patients with multiple myeloma (MM) are diagnosed with high-risk disease and have poor prognosis. Clinical trial data supports the combined use of selinexor, bortezomib, and dexamethasone (XVd) for treatment of patients with MM who have received at least 1 prior therapy. Information on the efficacy of XVd and of subsequent allogeneic stem cell transplantation (SCT) in heavily pretreated patients with high-risk MM is limited. CASE REPORT We present a case of a 58-year-old woman with high-risk MM (revised International Staging System Stage III; serum ß₂-mic

Совпадение в полном тексте источника
… Prevention of nausea may be explained by the fact that according to the selinexor best clinical practice recommendations [ 17 ], the patient received 2 prophylactic anti-emetics: granisetron and metoclopramide. …

Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics.

Cannabidiol (CBD) is an easily accessible and affordable Marijuana (Cannabis sativa L.) plant derivative with an extensive history of medical use spanning thousands of years. Interest in the therapeutic potential of CBD has increased in recent years, including its anti-tumour properties in various cancer models. In addition to the direct anticancer effects of CBD, preclinical research on numerous cannabinoids, including CBD, has highlighted their potential use in: (i) attenuating chemotherapy-induced adverse effects and (ii) enhancing the efficacy of some anticancer drugs. Therefore, CBD is ga

The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings.

BACKGROUND: This research aimed to quantify the burden of illness (BoI) in transplant eligible (TE) and transplant non-eligible (TNE) newly diagnosed multiple myeloma (NDMM) patients and their caregivers, in the first year after diagnosis: at months 0, 3, and 12. METHODS: Prospective, cross-sectional, observational NDMM study of TE and TNE patients and their caregivers from France, Germany, Italy, and Spain was conducted between May 2019 and January 2021. A structured, online questionnaire measuring disease burden, direct and costs, out-of-pocket expenses, and health-related quality of life (

Совпадение в полном тексте источника
… 12 (n=77) Month 0 (n=96) Month 3 (n=100) Month 12 (n=107) Pain killers Opioids 16% 33% 52% 58% 51% 78% Non-opioid OTC painkillers 34% 56% 39% 28% 36% 10% Other medication Corticosteroids 16% 54% 21% 24% 15% 10% Bisphosphonates 7% 32% 13% 12% 12% 8% Anti-diarrhea treatments 19% 47% 25% 5% 3% 10% Anti-emetics … | 10% | 56% | 22% | 8% | 12% | 8% Other | 2% | 35% | 9% | 0% | 2% | 7% No medication for MM | | 40% | 5% | 9% | 8% | 6% | 10% Consistent with the appearance of treatment-related side-effects, use of anti-diarrhea and anti-emetic medications increased amongst TE patients three months after diagnosis …

Review of oncological emergencies in small animal patients.

Oncological emergencies can occur at any time during the course of a malignancy and need to be recognized promptly to maximize successful outcomes. Emergencies are characterized as chemotherapy-induced, paraneoplastic syndromes, or directly related to the neoplasm. Prompt identification with treatment of these emergencies can prolong survival and improve quality of life, even in the setting of terminal illness. This review aims to educate the reader on the pathophysiology, clinical presentation and treatment of some of these emergencies, and to review the current veterinary literature to help

Совпадение в полном тексте источника
… Anti‐emetics can also be administered with the parenteral route preferred. Commonly used antiemetics include maropitant and ondansetron. For patients experiencing severe GI side effects, intravenous fluid therapy is recommended. … For a full review of these anti‐emetics, the reader is directed elsewhere (Vail 2009 ; Whitehead et al . 2016 ). …

Оценка связанных с администрацией реакций с подкожной ДАТРАТУМАБ с прелестным лечением и без него.

Для лечения расстройств плазменных клеток часто используется фон Daratumumab-hyaluronidase-fihj (Dara-SQ), что связано с улучшением исхода. Было установлено, что " Dara-SQ " не является следствием инъекции " daratumumab " ( " Dara-IV " ) с точки зрения эффективности, безопасности и сопряжена с меньшим числом ответных мер, связанных с администрацией (АРР). Несмотря на более низкий риск АРВ в случае с Dara-SQ, маркировка пакетов по-прежнему рекомендует неопределённую предлежащую аптечку. В этом исследовании мы изучили вопрос о безопасности пренебрежения после того,

Совпадение в полном тексте источника
… If additional supportive medications such as anti-emetics, intravenous fluids, electrolyte supplementation, or vaccines were administered at a given visit, the therapy time savings would not be calculated for that Dara-SQ dose. …

DNA Damaging Drugs

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Adverse Effects For the comfort of the patient, nitrogen mustard may be given at bedtime, following administration of a barbiturate and an anti-emetic to minimize the adverse effects of nausea and vomiting, which usually occurs after 1–3 h. … Prior administration of anti-emetics is effective in diminishing and sometimes preventing this toxicity. Nausea and vomiting can also be reduced if lomustine is administered to fasting patients. …

The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.

Purpose of reviewThis document critically examines the role of cannabinoids in cancer care during an era marked by rapid advancements in oncology and changing perceptions on cannabis. It traces the historical context of cannabis in medicinal use, navigating its journey from widespread acceptance, subsequent criminalization, to its resurgence in modern therapeutic applications, particularly within the framework of Evidence-Based Medicine (EBM).Recent findingsAnchored in EBM principles, this study synthesizes current research from clinical trials, systematic reviews, and meta-analyses to evaluat

Efficacy and safety of acupuncture for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trial.

OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) represents a common and debilitating side effects in cancer patients, often compromising treatment adherence and quality of life. Current management remains suboptimal, necessitating the exploration of complementary therapies. Acupuncture, as a widely used adjunctive therapy, has been attempted for the treatment of CINV. This study aims to systematically evaluate the effect and safety of acupuncture in managing CINV. METHODS: We comprehensively searched seven electronic databases (EMBASE, Cochrane Library, Web of Science, PubMed, Chin

Multiple Myeloma

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… When using this medication, the use of prophylactic anti-emetics and close monitoring of counts is advised. Selinexor has a novel mechanism of action that exhibited effect against the disease as a monotherapy in heavily pretreated patients. …

Cyclic nucleotide phosphodiesterases as drug targets.

Cyclic nucleotides are synthesized by adenylyl and/or guanylyl cyclase, and downstream of this synthesis, the cyclic nucleotide phosphodiesterase families (PDEs) specifically hydrolyze cyclic nucleotides. PDEs control cyclic adenosine-3',5'monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) intracellular levels by mediating their quick return to the basal steady state levels. This often takes place in subcellular nanodomains. Thus, PDEs govern short-term protein phosphorylation, long-term protein expression, and even epigenetic mechanisms by modulating cyclic nucleotide levels

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for multiple myeloma (MM) patients. Although outpatient ASCT has been shown to be safe and feasible, the procedure is overall rare with most patients in the US undergoing inpatient ASCT. Furthermore, hospitalization rates for patients that undergo outpatient ASCT remain high. Adequate markers that predict hospitalization during outpatient ASCT are lacking, yet would be of great clinical value to select patients that are suited to outpatient ASCT. In this study we aimed to elucidate diffe

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.

The therapeutic options available for patients with multiple myeloma have greatly expanded over the past decade and incorporating these novel agents into routine clinical practice has significantly improved outcomes. The next generation of therapeutics is available for relapsed and refractory patients either as standard of care or in clinical trial, and these drugs represent a generational paradigm shift. Patients now have access to a multitude of novel immunotherapeutics, including monoclonal antibodies, an antibody-drug conjugate, chimeric antigen receptor T-cells (CAR-T), and bispecific T-c

Совпадение в полном тексте источника
… Based on drug tolerability, these anti-emetics may be weaned off following two cycles of treatment. … Child-Pugh Class C) Infectious disease | Antibacterial (fluoroquinolone) and anti-PJP prophylaxis (TMP-SMX) may be considered, especially in the first two cycles, given increased incidence of pneumonia Diarrhea | Given the incidence of grade 3 or higher nausea and diarrhea, anti-diarrheals and anti-emetics …

Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma.

Follicular dendritic cell sarcoma (FDCS) is a rare, low- to intermediate-grade malignancy arising from mesenchymal-derived follicular dendritic cells, which can also present with high-grade pathological features and may rapidly become fatal. Conventional therapeutic strategies, primarily consisting of surgical resection with adjunctive systemic chemotherapy, such as gemcitabine-docetaxel, ifosfamide, doxorubicin, or other regimens, remain inconsistently effective, with median survival notably reduced in advanced or recurrent disease. Given the limited therapeutic options and frequent relapse,

Совпадение в полном тексте источника
… Throughout the course of treatment with lenalidomide 10mg once daily, patient denied side effects and did not require anti-emetics, other supportive medications, or dose reductions. By 2019, imaging indicated stable disease with no new metastases. …

Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis.

High-dose melphalan (HDM) is the standard conditioning regimen before autologous stem cell transplantation (ASCT) in plasma cell malignancies. Despite prophylactic antiemetics, chemotherapy-induced nausea and vomiting (CINV) remains a prevalent challenge. We retrospectively compared the efficacy of netupitant and palonosetron (NEPA) plus dexamethasone with that of serotonin receptor antagonist (5-HT3RA)-based regimens (the control group) for patients receiving HDM. The primary endpoint was complete resolution (CR) of CINV in the acute (0-24 hours) and delayed (24-168 hours) phases. Secondary e…

15 years supporting adherence to oral anti-cancer treatment: use of the MASCC Oral Agent Teaching Tool (MOATT) worldwide, a review for the future.

IntroductionThe MASCC Oral Agent Teaching Tool (MOATT®) was developed to address the challenges of patient education and adherence in the context of oral anticancer agents. Despite its evidence-based design and global availability, there is limited documentation on its application in clinical practice and research. This review aims to assess the extent of MOATT usage and evaluate the impact on patient outcomes.MethodsA scoping review was conducted following Joanna Briggs Institute and PRISMA-ScR reporting standards. Databases included CINAHL, Embase, PsycInfo, Web of Science, and PubMed. Inclu

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.

BackgroundPatients with advanced/recurrent endometrial cancer have a poor prognosis and limited treatment options. Biomarkers such as tumor protein 53 (TP53) in endometrial cancer can integrate novel strategies for improved and individualized treatment that could impact patient outcomes. In an exploratory analysis of the phase III ENGOT-EN5/GOG-3055/SIENDO study of selinexor maintenance monotherapy 80 mg in advanced/recurrent endometrial cancer, a pre-specified subgroup of patients with TP53 wild type (wt) endometrial cancer showed preliminary activity at long-term follow-up with a generally m

Совпадение в полном тексте источника
… Patients unable to tolerate two forms of anti-emetics prior to each dose for at least two cycles will not be eligible for the trial. Active, ongoing, or uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week of screening. …

Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.

CONTEXT: Myeloma bone disease (MBD) is a devastating complication of multiple myeloma that leads to severe pain. OBJECTIVES: The aim of this study was to evaluate the efficacy and tolerability of tapentadol prolonged release (PR) in the management of patients with MBD suffering from moderate-to-severe cancer pain. METHODS: A 12-week prospective study was carried out in 25 opioid-naïve MBD patients. Patients initially received twice-daily doses of tapentadol PR 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity. The following parameters were recorded at weekl

Совпадение в полном тексте источника
… Symptomatic drugs (anti-emetics and laxatives), corticosteroids, bisphosphonates, radiotherapy, and chemotherapy were used according to clinical needs. Patients were visited or contacted at least once weekly to monitor therapy and adjust it if needed, according to the clinical status. …

Талидомид взаимодействует с воспалением в идиопатическом фиброзе легких.

" Трагедия Талидомида " является важной вехой в истории фармацевтической промышленности. Несмотря на ограниченные клинические испытания, прилагаются постоянные усилия по изучению Талидомида в качестве лекарства от рака и подстрекательских заболеваний, таких, как ревматуидный артрит, проказа, и COVID-19. В рамках этого обзора основное внимание уделяется возможностям борьбы с воспалением путем повторного использования талидомида для лечения идиопатического фиброза легких (ИПФ). Статьи были найдены в базе данных Scopus, сортированы и рассмотрены отдельные статьи. Содержание включает в с

Нейрофармакология каннабиноидов: всеобъемлющий обзор доклинических и клинических данных о экстрактах гемп-деривных веществ и активных соединениях.

Каннабис сатива содержит более 120 фитоканнабиноидов, причем наиболее характерными из них являются Δ9-тетрагидроканнабинол (THC) и каннабидиол (CBD). В настоящем обзоре обобщаются доклинические и клинические данные об экстрактах гематома, каннабиноидах и активных соединениях. THC действует главным образом как частичный агонист каннабиноидного рецептора типа 1 (CB1) и типа 2 (CB2), приводящий к психоактивным, аппетитным, антиэметическим и анальгетическим эффектам. КБР не является опьяняющим и имеет мультимодальный профиль, включающий негативную аллостерическую модуляцию CB1, обратное агонизм CB